109 filings
Page 2 of 6
8-K
knn tddzk7f00jvgnm
24 Sep 21
Departure of Directors or Certain Officers
4:09pm
8-K
gj8 sjejcznqg
12 Aug 21
Sio Gene Therapies Announces Corporate Updates and Fiscal First Quarter 2021 Financial Results
7:22am
8-K
lum 35un0pfrb7gl6
9 Jun 21
Sio Gene Therapies Announces Fiscal Year 2020 Year-End Financial Results and Expected Fiscal Year 2021 Key Milestones
7:02am
8-K
kuxnjs5 hjv8jwc5h
13 May 21
Sio Gene Therapies Announces CSF Reductions in GM1 Ganglioside from Clinical Trial of AXO-AAV-GM1 Gene Therapy
7:01am
8-K
q2hv00c6g orhezg
5 Apr 21
Departure of Directors or Certain Officers
5:10pm
8-K
q14trgw
15 Mar 21
Sio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1 Gangliosidosis Program Milestones
7:02am
8-K
6e58iq
9 Feb 21
Results of Operations and Financial Condition
7:02am
8-K
l8w49x3zuz2o525z9zy
4 Feb 21
Sio Gene Therapies Announces Receipt of $11.6 Million from Closing of the Sale of Arvelle Therapeutics
7:02am
8-K
fn61jize9fb 5ay
3 Feb 21
Regulation FD Disclosure
7:03am
8-K
6s4uuldxd2zr c1beits
4 Jan 21
Sio Gene Therapies to sell Arvelle Stake as part of Angelini Pharma’s Acquisition of Arvelle Therapeutics
8:01am
8-K
ix0v2 gnjytgv6ef2ks
18 Dec 20
Entry into a Material Definitive Agreement
6:00am
8-K
rcvci
15 Dec 20
Sio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase 1/2 Trial of AXO-AAV-GM1 for GM1 Gangliosidosis
4:04pm
8-K
1y46o1uht73o12fx
13 Nov 20
Results of Operations and Financial Condition
7:03am
8-K
6wnvi 311z8k0vl1o3
10 Nov 20
Axovant Gene Therapies Announces Name Change to Sio Gene Therapies
7:02am
8-K
8u1fp6 zdgkd3w
9 Nov 20
Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases
7:00am
8-K
cky27 kcwdhdh
29 Oct 20
Regulation FD Disclosure
4:03pm
8-K
squ2z89quh6ecbklur
13 Oct 20
Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff Disease
7:01am
8-K
qq2tda a3h1ad2cpc0q7
9 Oct 20
Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis
7:00am
8-K
2zruha1wm ea4j5nif
8 Oct 20
Departure of Directors or Certain Officers
7:16am
8-K
rzog2hkpeix6y9
6 Oct 20
Axovant Gene Therapies Announces Positive Six-month Follow-up Data from Second
7:14am